GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Cyclically Adjusted Price-to-FCF

Zogenix (Zogenix) Cyclically Adjusted Price-to-FCF : (As of May. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zogenix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zogenix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Zogenix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Cyclically Adjusted Price-to-FCF Chart

Zogenix Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zogenix Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zogenix's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Zogenix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zogenix's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zogenix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Zogenix's Cyclically Adjusted Price-to-FCF falls into.



Zogenix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Zogenix's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2021 is calculated as:

For example, Zogenix's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2021 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=-0.734/117.6295*117.6295
=-0.734

Current CPI (Dec. 2021) = 117.6295.

Zogenix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201203 -1.815 96.783 -2.206
201206 -1.824 96.819 -2.216
201209 -1.258 97.633 -1.516
201212 -0.677 96.871 -0.822
201303 -1.262 98.209 -1.512
201306 -0.751 98.518 -0.897
201309 -0.734 98.790 -0.874
201312 -0.673 98.326 -0.805
201403 -1.257 99.695 -1.483
201406 -1.022 100.560 -1.195
201409 -1.732 100.428 -2.029
201412 -0.510 99.070 -0.606
201503 -1.148 99.621 -1.356
201506 -1.092 100.684 -1.276
201509 -0.359 100.392 -0.421
201512 -0.558 99.792 -0.658
201603 -0.870 100.470 -1.019
201606 -0.607 101.688 -0.702
201609 -0.724 101.861 -0.836
201612 -0.746 101.863 -0.861
201703 -0.461 102.862 -0.527
201706 -0.588 103.349 -0.669
201709 -0.804 104.136 -0.908
201712 -0.864 104.011 -0.977
201803 -0.713 105.290 -0.797
201806 -0.871 106.317 -0.964
201809 -0.705 106.507 -0.779
201812 -0.698 105.998 -0.775
201903 -0.695 107.251 -0.762
201906 -0.502 108.070 -0.546
201909 -4.916 108.329 -5.338
201912 -0.862 108.420 -0.935
202003 -1.124 108.902 -1.214
202006 -0.596 108.767 -0.645
202009 -0.852 109.815 -0.913
202012 -0.797 109.897 -0.853
202103 -0.968 111.754 -1.019
202106 -0.769 114.631 -0.789
202109 -0.848 115.734 -0.862
202112 -0.734 117.630 -0.734

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zogenix  (NAS:ZGNX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Zogenix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Zogenix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Zogenix (Zogenix) Business Description

Industry
Traded in Other Exchanges
N/A
Address
5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Executives
Erle T Mast director C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner director PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick director C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts director C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar officer: EVP & CHIEF COMMERCIAL OFFICER C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel officer: EVP/Chief Development Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer officer: EVP/Chief Medical Officer C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr director, officer: President and CEO [email protected] EMERYVILLE CA 94608
Mark C Wiggins director 12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock director C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer director
Shawnte Mitchell officer: EVP, GC and Secretary 5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith officer: EVP, CFO, Treasurer & Sec. 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5

Zogenix (Zogenix) Headlines